Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 17 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Engages IBN for Corporate Communications Expertise
Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) is a junior resource company focused on monetizing high-grade…
-
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research
Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective…
-
ONAR Holding Corp. (ONAR) Is ‘One to Watch’
ONAR is scaling a diversified, AI-driven marketing network addressing multiple high-growth industry verticals. The company…